ASCO Updates Adjuvant Endocrine Therapy Guidelines for Postmenopausal Women
There are currently three FDA-approved aromatase inhibitors indicated for adjuvant treatment of breast cancer (BC) in postmenopausal women: letrozole, anastrozole, and exemestane. The American Society of Clinical Oncology recently updated its clinical practice guidelines on adjuvant endocrine therapy for postmenopausal women with hormone receptor–positive BC. Read more.

Effect of Chemo Dose Among Early Breast Cancer Patients
Standard combination chemotherapy reduces mortality by about one-third in patients with early breast cancer. The optimal dosage and timing of these agents, however, is not known, and it has been hypothesized that dose-dense regimens may enhance tumor-cell kill rates, decrease tumor regrowth, and improve the chances of cure. Read more.